Publicaciones en las que colabora con Fernando Lecanda Cordero (17)

2023

  1. ENPP1 Immunobiology as a Therapeutic Target

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 12, pp. 2184-2193

  2. LAMC2 Regulates Key Transcriptional and Targetable Effectors to Support Pancreatic Cancer Growth

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 6, pp. 1137-1154

  3. Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer

    Nature Communications, Vol. 14, Núm. 1

2022

  1. Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis

    Cancer Letters, Vol. 529, pp. 70-84

  2. Tumor ENPP1 (CD203a)/Haptoglobin Axis Exploits Myeloid-Derived Suppressor Cells to Promote Post-Radiotherapy Local Recurrence in Breast Cancer

    Cancer Discovery, Vol. 12, Núm. 5, pp. 1356-1377

2021

  1. Dose volume histogram constraints in patients with head and neck cancer treated with surgery and adjuvant HDR brachytherapy: A proposal of the head and neck and skin GEC ESTRO Working group

    Radiotherapy and Oncology, Vol. 154, pp. 128-134

  2. FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted

    Journal of Hepatology, Vol. 75, Núm. 2, pp. 363-376

2020

  1. Short-term starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockade

    Nature cancer, Vol. 1, Núm. 1, pp. 75-85

  2. The Mir181ab1 cluster promotes KRAS-driven oncogenesis and progression in lung and pancreas

    Journal of Clinical Investigation, Vol. 130, Núm. 4, pp. 1879-1895

2019

  1. Long-term results of Perioperative High Dose Rate Brachytherapy (PHDRB) and external beam radiation in adult patients with soft tissue sarcomas of the extremities and the superficial trunk: Final results of a prospective controlled study

    Radiotherapy and Oncology, Vol. 135, pp. 91-99

2018

  1. Erratum: Perioperative high-dose-rate brachytherapy in locally advanced and recurrent gynecological cancer: Final results of a Phase II trial (Brachytherapy (2018) 17(5) (734–741), (S1538472118300898) (10.1016/j.brachy.2018.04.007))

    Brachytherapy

  2. Perioperative high-dose-rate brachytherapy in locally advanced and recurrent gynecological cancer: Final results of a Phase II trial

    Brachytherapy, Vol. 17, Núm. 5, pp. 734-741

2017

  1. An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer

    Nature Communications, Vol. 8

  2. EPCR promotes breast cancer progression by altering SPOCK1/testican 1-mediated 3D growth

    Journal of Hematology and Oncology, Vol. 10, Núm. 1, pp. 1-12

2011

  1. Synergistic effects of CTLA-4 blockade with tremelimumab and elimination of regulatory T lymphocytes in vitro and in vivo

    International Journal of Cancer, Vol. 129, Núm. 2, pp. 374-386

  2. Tumor-stromal interactions of the bone microenvironment: In vitro findings and potential in vivo relevance in metastatic lung cancer models

    Clinical and Experimental Metastasis, Vol. 28, Núm. 8, pp. 779-791

2006

  1. Las metástasis óseas del cáncer

    Anales del sistema sanitario de Navarra, Vol. 29, Núm. 2, pp. 177-187